论我国药品不良反应损害救济制度  

On the Damage Relief System of Adverse Drug Reactions in China

作　　者：徐继红[1] 王晓[2] 

机构地区：[1]江西中医药大学经济与管理学院 [2]江西中医药大学

出　　处：《医学与法学》2014年第1期49-51,共3页Medicine and Jurisprudence

基　　金：四川医事卫生法治研究中心立项资助项目"我国药品不良反应救济制度研究"(项目编号:YF11-Y09)的阶段性成果

摘　　要：尽管药品不良反应事件近年来频发,但因我国至今仍无专门的药品不良反应损害救济立法,致使受害人合法权益无法得到较好保护。在世界经济一体化的今天,由国外药品大量进口而引发的药品不良反应在所难免;依据冲突规范,由药品进口而引发的药品不良反应案件适用侵权行为地法,但我国公民却将因我国缺乏完善的法律依据而难以获得赔偿。鉴此,构建我国药品不良反应救济制度已刻不容缓。In recent years, events of adverse drug reactions occurred frequently, but legitimate rights and in terests of victims can not be guaranteed because of no legislation on adverse drug reactions in our country. In to day＇s world economic integration, adverse drug reactions are inevitable caused by massive imports of foreign drugs. According to the conflict rules, adverse drug reactions caused by import drugs should adopt the local tort laws, therefore, we Chinese people will not be compensated for the lack of a sound legal basis. Therefore, it is ur gent to establish adverse drug reaction relief system in China.

关 键 词：药品不良反应 损害救济 认定 归责原则 

分 类 号：R95[医药卫生—药学]